At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 430 enrolled
Drug / intervention
Standardized Ragweed Allergenic Extract +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused By Ragweed Pollen
In Brief
A Phase 3 clinical trial evaluating Standardized Ragweed Allergenic Extract and Placebo for Allergic Rhinitis. Completed, enrolled 430 participants across 30 sites.
Detailed Summary
The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartMar 2008
Primary CompletionNov 2008
Study CompletionDec 2008
TodayJul 2026
First PostedJan 24, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.4 years ago
Interventions
Standardized Ragweed Allergenic Extractbiological
Standardized Ragweed Allergenic Extract, sublingual oral
Placebobiological
Placebo, sublingual oral